AdvanTIG-202: Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Previously Treated Recurrent or Metastatic Cervical Cancer

NCT04693234 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

178

Enrollment

INDUSTRY

Sponsor class

Conditions

Cervical Cancer

Interventions

BIOLOGICAL: Tislelizumab
BIOLOGICAL: Ociperlimab

Sponsor

BeiGene